Evidence map›Paper›PMID 26011900›Full record

ReviewNutrition reviews2015

Clinical applications of bioactive milk components.

David R Hill, David S Newburg

Open access · bronzeAbstract readReview
In one paragraph

Review in Nutrition reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Human Milk, More Than Simple Nourishment.Children (Basel, Switzerland) · 2021
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Breast Milk: A Meal Worth Having.Frontiers in nutrition · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David R Hill
David S Newburg
Boston College · US

Funding

VIRAL GASTROENTERITIS PATHOGENSP01HD013021 · NICHD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI RUIZ-PALACIOS, GUILLERMO · 1985 to 2013
$15.0M
Novel broad spectrum therapeutic glycans against Category B pathogensU01AI075563 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI NEWBURG, DAVID S. · 2007 to 2011
$4.5M
Oligosaccharide moieties of human milk glycans that inhibit pathogensR01HD061930 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI NEWBURG, DAVID S. · 2009 to 2014
$3.0M
NIAID NIH HHS U01 AI075563NIAID NIH HHS U01AI075563NICHD NIH HHS P01 HD013021NICHD NIH HHS P01HD013021NICHD NIH HHS R01 HD061930NICHD NIH HHS R01HD061930PHS HHS R01H059140
6 · The paper itself

Abstract

Milk represents a unique resource for translational medicine: It contains a rich pool of biologically active molecules with demonstrated clinical benefits. The ongoing characterization of the mechanistic process through which milk components promote development and immunity has revealed numerous milk-derived compounds with potential applications as clinical therapies in infectious and inflammatory disease, cancer, and other conditions. Lactoferrin is an effective antimicrobial and antiviral agent in high-risk patient populations and a potentially potent adjuvant to chemotherapy in lung cancer. Enteric nutrition formulas supplemented with transforming growth factor β, a milk cytokine, have been shown to promote remission in pediatric Crohn's disease. A number of milk glycans, including human milk oligosaccharides, show promise in preclinical studies as antimicrobial and anti-inflammatory agents. While active preclinical investigations of human milk may soon result in large-scale production of human milk molecules, bovine milk components in many instances represent a practical source of bioactive milk compounds for use in clinical trials. This review summarizes current efforts to translate the compounds derived from human and bovine milk into effective clinical therapies. These efforts suggest a common pathway for the translation of milk-derived compounds into clinical applications.

Indexed as

AnimalsAnti-Infective AgentsAnti-Inflammatory AgentsAntineoplastic AgentsCaseinsCattleCell Line, TumorCrohn DiseaseHumansLactalbuminLactoferrinMilkMilk, HumanOligosaccharidesRandomized Controlled Trials as TopicTransforming Growth Factor betaAnti-Infective AgentsAnti-Inflammatory AgentsAntineoplastic AgentsCaseinsLactalbuminLactoferrinOligosaccharidesTransforming Growth Factor beta

Identifiers

PMID26011900
PMCPMC4560033
OpenAlexW1961766403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.